CLINICAL UPDATES
 
PARP inhibitors may mark new era in prostate cancer care
Urologists, oncologists, and prostate cancer patients are entering a new era in prostate cancer therapy—one that is going to be genetically defined.
Experts discuss treatments
 
Selective bladder denervation found efficacious in refractory OAB
Selective bladder denervation appears to be an effective treatment for refractory overactive bladder patients, lasting up to 12 months regardless of whether the patient exhibits detrusor overactivity at baseline, according to a recent study from Canada.
Learn more
 
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
 
MORE FROM UROLOGY TIMES
 
OAB treatment efficacy similar in frail, nonfrail patients
Fusion transcript shows potential for prostate cancer biomarker
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont